USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: A Perfusable, Revascularized, Cardiac-Derived Patch for the…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
1142525
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
Miromatrix Medical Inc.
18683 Bearpath Trail Eden Prairie, MN 55347-3476
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: SBIR Phase I: A Perfusable, Revascularized, Cardiac-Derived Patch for the Treatment of Heart Disease
Agency: NSF
Contract: 1142525
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovations Research (SBIR) Phase I proposal is to demonstrate the feasibility of using Miromatrix' perfusion decellularization technology to create a fully revascularized cardiac patch for the treatment of ischemic heart disease and congenital heart repair. While medical advancements have decreased the overall mortality rate for acute myocardial infarction (MI) patients, therapeutic options are lacking to address the underlying loss of myocardial tissue, resulting in a mortality rate greater than 33% at five years. For congenital repair, current surgical approaches for cardiac reconstruction utilize synthetic materials that do not have the ability to grow and remodel with the patient. The proposed cardiac-derived revascularized cardiac patch may promote faster reconstruction of functional tissue by providing a fully perfusable scaffold with a composition and architecture similar to native cardiac tissue. The broader/commercial impacts of this research are the development of a revascularized cardiac patch to treat ischemic heart failure and congenital repair. Inhibiting the onset or delaying the severity of heart failure will have a significant effect on reducing the treatment cost of heart failure, which currently is estimated at over $37 billion. This product with have significant advantages over existing technologies, including: 1) full thickness, biological, cardiac-derived matrix material; 2) vascular supply to support migrating cells and remodeling; 3) superior mechanical properties; and, 4) no need for immunosuppressive therapies. Moreover, this will be the first cardiac-derived, revascularized patch available for treating ischemic areas of the heart.

Principal Investigator:

Jeffrey J. Ross
6122027026
jross@miromatrix.com

Business Contact:

Jeffrey J. Ross
6122027026
jross@miromatrix.com
Small Business Information at Submission:

Miromatrix Medical Inc.
18683 Bearpath Trail Eden Prairie, MN 55347-3476

EIN/Tax ID: 271285782
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No